Study subjects
abnormal blood panel, hypoglycemic episodes, anemia, T1D, cardiac rhythm abnormality
EVENT, ANEMIA, COMPLICATIONS
Eligible subjects were adults (≥18 years of old) with a clinical diagnosis of T1D for at least 1 year, treated with either multiple daily insulin injections (MDI) or continuous subcutaneous insulin injection (CSII) and a glycated hemoglobin HbA1c ≤ 89 mmol/mol (≤10%). Exclusion criteria included clinically significant microvascular complications, recent (<3 months) acute macrovascular event, significant cardiac rhythm abnormality, abnormal blood panel and/or anemia (hemoglobin < 100 g/L), ongoing pregnancy or breastfeeding, severe hypoglycemic episodes within 1 month of screening, or additional health problems that could affect the participation to the study as per medical assessment of the recruiting physician.The ethics committee at Montreal Clinical Research Institute approved the study that was conducted according to the Declaration of Helsinki. All participants provided written informed consent. Subjects were recruited at the Montreal Clinical Research Institute (IRCM) through the T1D clinic and from a pool of participants who had participated in previous study protocols. The study followed a block balanced randomization and envelopes were not opened until a participant had met the inclusion criteria and signed the informed consent.